Lipella Operating Cycle from 2010 to 2026
| LIPO Stock | 0.19 0.05 20.83% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 51.88 | Current Value 60.7 | Quarterly Volatility 60.72446093 |
Check Lipella Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipella Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 K, Interest Expense of 0.0 or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 5.1, Dividend Yield of 0.0 or PTB Ratio of 1.57. Lipella financial statements analysis is a perfect complement when working with Lipella Pharmaceuticals Valuation or Volatility modules.
Lipella | Operating Cycle | Build AI portfolio with Lipella Stock |
Evaluating Lipella Pharmaceuticals's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Lipella Pharmaceuticals Common's fundamental strength.
Latest Lipella Pharmaceuticals' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Lipella Pharmaceuticals Common over the last few years. It is Lipella Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipella Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Lipella Operating Cycle Regression Statistics
| Arithmetic Mean | 65.52 | |
| Geometric Mean | 52.50 | |
| Coefficient Of Variation | 92.67 | |
| Mean Deviation | 37.59 | |
| Median | 44.07 | |
| Standard Deviation | 60.72 | |
| Sample Variance | 3,687 | |
| Range | 199 | |
| R-Value | 0.29 | |
| Mean Square Error | 3,607 | |
| R-Squared | 0.08 | |
| Significance | 0.26 | |
| Slope | 3.46 | |
| Total Sum of Squares | 58,999 |
Lipella Operating Cycle History
About Lipella Pharmaceuticals Financial Statements
Lipella Pharmaceuticals investors utilize fundamental indicators, such as Operating Cycle, to predict how Lipella Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 51.88 | 60.70 |
Pair Trading with Lipella Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Lipella Stock
Moving against Lipella Stock
| 0.87 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.78 | DSGN | Design Therapeutics | PairCorr |
| 0.65 | ENGN | enGene Holdings Common | PairCorr |
| 0.58 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.54 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.
The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Lipella Pharmaceuticals Correlation against competitors. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Will Biotechnology sector continue expanding? Could Lipella diversify its offerings? Factors like these will boost the valuation of Lipella Pharmaceuticals. Expected growth trajectory for Lipella significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipella Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.33) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lipella Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipella Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lipella Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.